CYP450 enzyme interactions and medication safety This is the section most online resources skip entirely, and it may be the most important for researchers on multiple medications
Researchers also associate ending GLP-1 therapy before pregnancy with a few risks.* Women who stopped taking a GLP-1 RA before or during early pregnancy had roughly 1.3x the risk of preterm birth, gestational diabetes, and high blood pressure conditions during pregnancy, compared to similar women who had not taken a GLP-1 RA
Alcoholic liver disease: utility of animal models
2022, doi: 10.1016/j.cub.2022.07.020
Water, stabilizer polydextrose, acidity regulator citric acid, carbon dioxide, cola emulsion (flavouring, colouring E 150d), L-carnitine, taurine, preservatives (potassium sorbate, sodium benzoate), sweeteners (acesulfame K, sucralose), caffeine